
Novacyt S.A (ALNOV) | Financial Analysis & Statements
Novacyt S.A. | Small-cap | Healthcare
Novacyt S.A. | Small-cap | Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2018Income Metrics
EPS (Diluted)
€0.00
Balance Sheet Metrics
Total Assets
81.5M
Total Liabilities
26.3M
Shareholders Equity
55.3M
Debt to Equity
0.48
Cash Flow Metrics
Revenue & Profitability Trend
Novacyt S.A Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 22.7M | 12.3M | 24.4M | 92.6M | 277.2M |
Cost of Goods Sold | -14.4M | 8.3M | 17.7M | 64.4M | 65.7M |
Gross Profit | 37.1M | 4.0M | 6.7M | 28.2M | 211.5M |
Gross Margin % | 163.4% | 32.9% | 27.3% | 30.5% | 76.3% |
Operating Expenses | |||||
Research & Development | 3.2M | 3.3M | 5.8M | 4.6M | 1.6M |
Selling, General & Administrative | 48.1M | 15.7M | 6.0M | 7.4M | 5.7M |
Other Operating Expenses | 420.2K | 406.3K | 515.1K | 542.0K | 429.0K |
Total Operating Expenses | 51.7M | 19.4M | 12.3M | 12.6M | 7.8M |
Operating Income | -19.3M | -18.3M | -18.1M | 1.4M | 174.9M |
Operating Margin % | -84.9% | -149.0% | -74.5% | 1.5% | 63.1% |
Non-Operating Items | |||||
Interest Income | 3.5M | 4.0M | 901.7K | 396.0K | 46.0K |
Interest Expense | 5.9M | 2.8M | 530.1K | 120.0K | 1.6M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | -45.6M | -28.3M | -23.2M | -5.7M | 165.2M |
Income Tax | -847.3K | -408.6K | 2.5M | 349.0K | 32.7M |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 19.8% |
Net Income | -48.3M | -32.7M | -29.8M | -9.7M | 132.4M |
Net Margin % | -212.7% | -266.4% | -122.3% | -10.5% | 47.8% |
Key Metrics | |||||
EBITDA | -28.8M | -8.0M | -10.6M | 3.6M | 176.5M |
EPS (Basic) | €-0.59 | €-0.40 | €-0.36 | €-0.14 | €1.94 |
EPS (Diluted) | €-0.59 | €-0.40 | €-0.36 | €-0.14 | €1.94 |
Basic Shares Outstanding | 81749882 | 81749882 | 81749882 | 59403735 | 57352169 |
Diluted Shares Outstanding | 81749882 | 81749882 | 81749882 | 59403735 | 57352169 |
Income Statement Trend
Novacyt S.A Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 35.2M | 50.9M | 100.4M | 101.7M | 91.8M |
Short-term Investments | 9.2K | 10.4K | 10.4K | 9.0K | 9.0K |
Accounts Receivable | 3.7M | 31.5M | 29.2M | 30.2M | 79.2M |
Inventory | 2.6M | 3.5M | 3.5M | 11.5M | 29.9M |
Other Current Assets | - | - | - | - | - |
Total Current Assets | 45.5M | 99.8M | 146.9M | 158.8M | 205.0M |
Non-Current Assets | |||||
Property, Plant & Equipment | 0 | 0 | 0 | 0 | 2.3M |
Goodwill | 26.5M | 61.3M | 18.9M | 26.7M | 40.0M |
Intangible Assets | 20.3M | 11.8M | 3.6M | 3.7M | 4.3M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | - | - | - | 64.0K | 96.0K |
Total Non-Current Assets | 36.1M | 54.7M | 15.8M | 24.9M | 29.3M |
Total Assets | 81.5M | 154.5M | 162.7M | 183.7M | 234.3M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 533.4K | 2.7M | 321.0K | 1.4M | 5.2M |
Short-term Debt | 1.5M | 1.4M | 703.1K | 424.0K | 414.0K |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | 222.8K | - | 836.0K | 1.0M |
Total Current Liabilities | 7.2M | 34.1M | 28.0M | 38.9M | 74.1M |
Non-Current Liabilities | |||||
Long-term Debt | 12.3M | 14.4M | 303.6K | 1.4M | 2.0M |
Deferred Tax Liabilities | 5.1M | 2.6M | 1.2M | 1.2M | 800.0K |
Other Non-Current Liabilities | - | 833.5K | - | - | 812.0K |
Total Non-Current Liabilities | 19.1M | 19.6M | 1.7M | 3.0M | 9.4M |
Total Liabilities | 26.3M | 53.8M | 29.7M | 41.9M | 83.6M |
Equity | |||||
Common Stock | 4.7M | 4.7M | 4.7M | 4.1M | 4.1M |
Retained Earnings | -13.5M | 34.5M | 70.9M | 87.2M | 96.9M |
Treasury Stock | 130.5K | 159.3K | 105.1K | 78.0K | 49.0K |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 55.3M | 100.7M | 133.0M | 141.8M | 150.7M |
Key Metrics | |||||
Total Debt | 13.7M | 15.8M | 1.0M | 1.9M | 2.4M |
Working Capital | 38.3M | 65.7M | 118.9M | 119.9M | 130.8M |
Balance Sheet Composition
Novacyt S.A Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -48.2M | -32.7M | -29.7M | -9.7M | 132.4M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | 38.1M | 7.3M | 23.5M | 61.2M | -106.7M |
Operating Cash Flow | -8.8M | -25.0M | -5.7M | 51.4M | 25.6M |
Investing Activities | |||||
Capital Expenditures | -1.5M | -566.9K | -180.1K | -3.8M | -1.0M |
Acquisitions | -1.3M | -17.8M | -908.6K | -943.0K | -6.9M |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -2.8M | -18.4M | -1.1M | -4.7M | -7.8M |
Financing Activities | |||||
Share Repurchases | - | -54.3K | -15.0K | -29.0K | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | - | - | 0 |
Debt Repayment | 0 | -2.7M | 0 | 0 | -5.3M |
Financing Cash Flow | 133.9K | -2.3M | -15.0K | -29.0K | -4.2M |
Free Cash Flow | -12.7M | -26.6M | -16.3M | 11.6M | 101.8M |
Net Change in Cash | -11.4M | -45.7M | -6.8M | 46.7M | 13.5M |
Cash Flow Trend
Novacyt S.A Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-0.80
Forward P/E
1.83
Price to Book
0.70
Price to Sales
1.77
PEG Ratio
1.83
Profitability Ratios
Profit Margin
-212.73%
Operating Margin
-84.87%
Return on Equity
-57.28%
Return on Assets
-10.19%
Financial Health
Current Ratio
6.33
Debt to Equity
24.81
Beta
0.10
Per Share Data
EPS (TTM)
€-0.64
Book Value per Share
€0.68
Revenue per Share
€0.28
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
alnov | 34.8M | -0.80 | 0.70 | -57.28% | -212.73% | 24.81 |
Guerbet S.A | 293.8M | 18.03 | 0.73 | 3.50% | 1.89% | 100.91 |
Eurobio Scientific | 251.9M | 64.36 | 1.41 | 2.26% | 2.58% | 5.46 |
Median Technologies | 91.7M | -1.84 | - | 74.31% | -109.93% | -0.98 |
Affluent Medical | 60.0M | -4.30 | 1.95 | -48.69% | -275.50% | 0.54 |
Theraclion S.A | 31.4M | -5.58 | - | -203.90% | -346.01% | -66,510.16 |
Financial data is updated regularly. All figures are in the company's reporting currency.